JP2002201141A - 蛋白質合成抑制遺伝子の発現増強剤 - Google Patents

蛋白質合成抑制遺伝子の発現増強剤

Info

Publication number
JP2002201141A
JP2002201141A JP2001116710A JP2001116710A JP2002201141A JP 2002201141 A JP2002201141 A JP 2002201141A JP 2001116710 A JP2001116710 A JP 2001116710A JP 2001116710 A JP2001116710 A JP 2001116710A JP 2002201141 A JP2002201141 A JP 2002201141A
Authority
JP
Japan
Prior art keywords
ifn
gene
expression
subtype
enhancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001116710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002201141A5 (cg-RX-API-DMAC7.html
Inventor
Yoshiaki Yanai
嘉明 柳井
Tsukasa Sano
吏 佐能
Masashi Kurimoto
雅司 栗本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Hayashibara Biochemical Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Biochemical Laboratories Co Ltd filed Critical Hayashibara Biochemical Laboratories Co Ltd
Priority to JP2001116710A priority Critical patent/JP2002201141A/ja
Priority to CA002395324A priority patent/CA2395324A1/en
Priority to EP01972507A priority patent/EP1329223A4/en
Priority to KR1020027008401A priority patent/KR100830268B1/ko
Priority to US09/962,625 priority patent/US6773701B2/en
Priority to PCT/JP2001/008390 priority patent/WO2002036153A1/ja
Priority to TW090125438A priority patent/TWI283582B/zh
Publication of JP2002201141A publication Critical patent/JP2002201141A/ja
Priority to US10/777,081 priority patent/US7189389B2/en
Publication of JP2002201141A5 publication Critical patent/JP2002201141A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
JP2001116710A 2000-10-27 2001-04-16 蛋白質合成抑制遺伝子の発現増強剤 Pending JP2002201141A (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2001116710A JP2002201141A (ja) 2000-10-27 2001-04-16 蛋白質合成抑制遺伝子の発現増強剤
CA002395324A CA2395324A1 (en) 2000-10-27 2001-09-26 Expression potentiator for protein synthesis regulatory gene
EP01972507A EP1329223A4 (en) 2000-10-27 2001-09-26 EXPRESSION AMPLIFIER FOR PROTEIN SYNTHESIS OF REGULATORY GENES
KR1020027008401A KR100830268B1 (ko) 2000-10-27 2001-09-26 단백질 합성 억제 유전자의 발현 증강제
US09/962,625 US6773701B2 (en) 2000-10-27 2001-09-26 Expression enhancer for protein synthesis inhibitory genes
PCT/JP2001/008390 WO2002036153A1 (en) 2000-10-27 2001-09-26 Expression potentiator for protein synthesis regulatory gene
TW090125438A TWI283582B (en) 2000-10-27 2001-10-15 Expression potentiator for protein synthesis regulatory gene
US10/777,081 US7189389B2 (en) 2000-10-27 2004-02-13 Pharmaceutical composition of human interferon-α2 and interferon α8 subtypes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-328539 2000-10-27
JP2000328539 2000-10-27
JP2001116710A JP2002201141A (ja) 2000-10-27 2001-04-16 蛋白質合成抑制遺伝子の発現増強剤

Publications (2)

Publication Number Publication Date
JP2002201141A true JP2002201141A (ja) 2002-07-16
JP2002201141A5 JP2002201141A5 (cg-RX-API-DMAC7.html) 2008-05-15

Family

ID=26602905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001116710A Pending JP2002201141A (ja) 2000-10-27 2001-04-16 蛋白質合成抑制遺伝子の発現増強剤

Country Status (7)

Country Link
US (2) US6773701B2 (cg-RX-API-DMAC7.html)
EP (1) EP1329223A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002201141A (cg-RX-API-DMAC7.html)
KR (1) KR100830268B1 (cg-RX-API-DMAC7.html)
CA (1) CA2395324A1 (cg-RX-API-DMAC7.html)
TW (1) TWI283582B (cg-RX-API-DMAC7.html)
WO (1) WO2002036153A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089301A (ja) * 2003-09-12 2005-04-07 Hayashibara Biochem Lab Inc ウシの消化器疾患治療剤
WO2006095433A1 (ja) 2005-03-10 2006-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo ウシの消化器疾患治療剤
WO2007037098A1 (ja) 2005-09-27 2007-04-05 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 繁殖障害改善剤

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN104056254A (zh) * 2013-03-18 2014-09-24 赛德医药科技股份有限公司 用以降低肝炎病患复发率的组合物
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08126494A (ja) * 1994-11-01 1996-05-21 Kyoto Pasutouule Kenkyusho インターフェロン活性の測定法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5142199B2 (cg-RX-API-DMAC7.html) 1972-09-04 1976-11-13
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
JPS5639022A (en) 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS5654158A (en) 1979-10-09 1981-05-14 Hitachi Ltd Control system for call waiting
JP2838800B2 (ja) 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
US5503828A (en) * 1992-02-10 1996-04-02 Interferon Sciences, Inc. Alpha interferon composition and method for its production from human peripheral blood leukocytes
JP3232488B2 (ja) 1992-08-20 2001-11-26 株式会社林原生物化学研究所 プルラン高含有物とその製造方法並びに用途
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH07163368A (ja) 1993-12-15 1995-06-27 Hayashibara Biochem Lab Inc 組換えdnaとその組換えdnaを含む形質転換体
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08126494A (ja) * 1994-11-01 1996-05-21 Kyoto Pasutouule Kenkyusho インターフェロン活性の測定法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089301A (ja) * 2003-09-12 2005-04-07 Hayashibara Biochem Lab Inc ウシの消化器疾患治療剤
WO2006095433A1 (ja) 2005-03-10 2006-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo ウシの消化器疾患治療剤
WO2007037098A1 (ja) 2005-09-27 2007-04-05 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 繁殖障害改善剤
JPWO2007037098A1 (ja) * 2005-09-27 2009-04-02 株式会社林原生物化学研究所 繁殖障害改善剤

Also Published As

Publication number Publication date
EP1329223A1 (en) 2003-07-23
KR100830268B1 (ko) 2008-05-16
US6773701B2 (en) 2004-08-10
US20040197307A1 (en) 2004-10-07
US7189389B2 (en) 2007-03-13
CA2395324A1 (en) 2002-05-10
KR20020065620A (ko) 2002-08-13
EP1329223A4 (en) 2005-04-20
US20030039629A1 (en) 2003-02-27
TWI283582B (en) 2007-07-11
WO2002036153A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
Matikainen et al. Influenza A and sendai viruses induce differential chemokine gene expression and transcription factor activation in human macrophages
KR100223255B1 (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법
Wang et al. Extracellular role of HMGB1 in inflammation and sepsis
KR100537558B1 (ko) 인터류킨-18 결합 단백질
HUT77747A (hu) A BDNF és az NT-3 konjugátumai vízoldható polimerrel képezett konjugátumai
WO1990000397A1 (en) A pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
EA014157B1 (ru) РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2)
KR102249454B1 (ko) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
Masci et al. New and modified interferon alfas: preclinical and clinical data
CN103483443A (zh) 重组人干扰素样蛋白
US6773701B2 (en) Expression enhancer for protein synthesis inhibitory genes
EP1326628B1 (en) Chemokine mutants in the treatment of multiple sclerosis
JP3226918B2 (ja) 腫瘍壊死因子とインターロイキン−4の相乗作用
JPH0550273B2 (cg-RX-API-DMAC7.html)
Zheng et al. Yak IFNβ-3 enhances macrophage activity and attenuates Klebsiella pneumoniae infection
Lipiński et al. Protective effect of tissue ferritins in experimental Escherichia coli infection of mice in vivo
KR100530125B1 (ko) 개의난치성피부염의치료제및치료방법
US6774220B1 (en) Compounds having lectinic properties and their biological applications
RU2003334C1 (ru) Способ лечени больных с опухол ми
US20250082734A1 (en) Ptprs in autoimmunity
KR20200066628A (ko) 돼지 g-csf 변이체 및 그 용도
JPH1057080A (ja) L−アスパラギナーゼ活性を有する哺乳類由来のポリペプチド
JP4866612B2 (ja) 生理活性複合体
JPH09157180A (ja) 感受性疾患剤
JPS63190830A (ja) 抗悪性腫瘍剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120529